lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.
Company profile
Ticker
LTRN
Exchange
Website
CEO
Panna L. Sharma
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Lantern Pharma
SEC CIK
Corporate docs
Subsidiaries
Starlight Therapeutics Inc. • Lantern Pharma Australia Pty Ltd • Lantern Pharma Limited ...
IRS number
463973463
LTRN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
18 Mar 24
8-K
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
18 Mar 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Entry into a Material Definitive Agreement
24 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights
8 Nov 23
8-K
Other Events
20 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
Transcripts
LTRN
Earnings call transcript
2023 Q4
18 Mar 24
LTRN
Earnings call transcript
2023 Q3
8 Nov 23
LTRN
Earnings call transcript
2023 Q2
9 Aug 23
LTRN
Earnings call transcript
2023 Q1
9 May 23
LTRN
Earnings call transcript
2022 Q4
21 Mar 23
LTRN
Earnings call transcript
2022 Q3
8 Nov 22
LTRN
Earnings call transcript
2022 Q2
9 Aug 22
LTRN
Earnings call transcript
2022 Q1
4 May 22
LTRN
Earnings call transcript
2021 Q4
11 Mar 22
LTRN
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
SC 13D/A
Bios Equity Partners, LP
1 Mar 24
4
Aaron G.L. Fletcher
29 Feb 24
4
Leslie W. Kreis
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
SC 13G/A
ProPhase Labs, Inc.
14 Feb 24
4
Aaron G.L. Fletcher
19 Jan 24
4
Leslie W. Kreis
19 Jan 24
SC 13D/A
Bios Equity Partners, LP
1 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.57 mm | 25.57 mm | 25.57 mm | 25.57 mm | 25.57 mm | 25.57 mm |
Cash burn (monthly) | 1.13 mm | 1.19 mm | 1.17 mm | 1.40 mm | 1.20 mm | 1.14 mm |
Cash used (since last report) | 7.72 mm | 8.09 mm | 8.02 mm | 9.57 mm | 8.22 mm | 7.75 mm |
Cash remaining | 17.85 mm | 17.48 mm | 17.55 mm | 16.00 mm | 17.35 mm | 17.82 mm |
Runway (months of cash) | 15.8 | 14.7 | 14.9 | 11.4 | 14.4 | 15.7 |
Institutional ownership, Q3 2023
38.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 2 |
Closed positions | 5 |
Increased positions | 4 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 2.33 bn |
Total shares | 4.10 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bios Equity Partners | 1.97 mm | $13.80 mm |
PRPH ProPhase Labs | 910.00 k | $4.00 mm |
Green Park & Golf Ventures | 525.26 k | $10.11 mm |
GWM Advisors | 170.03 k | $579.83 mm |
Geode Capital Management | 95.04 k | $324.14 mm |
Carlson Capital L P | 95.00 k | $323.95 mm |
CM Management | 75.00 k | $255.75 mm |
Redmond Asset Management | 46.51 k | $158.59 mm |
Pathway Financial Advisors | 32.77 k | $111.75 mm |
Horizon Kinetics Asset Management | 30.00 k | $102.30 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 4,185 | 20.38 k | 137,832 |
29 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 13,686 | 66.65 k | 450,118 |
29 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 1,832 | 8.92 k | 60,256 |
29 Feb 24 | Leslie W. Kreis | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 4,185 | 20.38 k | 137,832 |
29 Feb 24 | Leslie W. Kreis | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 13,686 | 66.65 k | 450,118 |
29 Feb 24 | Leslie W. Kreis | Common Stock | Sell | Dispose S | Yes | No | 4.87 | 1,832 | 8.92 k | 60,256 |
28 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.85 | 15,780 | 76.53 k | 142,017 |
28 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.85 | 51,608 | 250.30 k | 463,804 |
28 Feb 24 | Fletcher Aaron G.L. | Common Stock | Sell | Dispose S | Yes | No | 4.85 | 6,909 | 33.51 k | 62,088 |
28 Feb 24 | Leslie W. Kreis | Common Stock | Sell | Dispose S | Yes | No | 4.85 | 15,780 | 76.53 k | 142,017 |
News
Lantern Pharma Approved To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer In Never-Smokers Into Japan and Taiwan
22 Apr 24
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
19 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
19 Mar 24
Recap: Lantern Pharma Q4 Earnings
18 Mar 24
Press releases
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
24 Apr 24
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
10 Apr 24
Thinking about buying stock in Archer Aviation, Lantern Pharma, Taysha Gene Therapies, Pagaya Technologies, or Blink Charging?
20 Mar 24
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
18 Mar 24
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
15 Mar 24